Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2011

View Archived Issues

Phase II data reported for S*BIO's SB-939

Phase III study of canakinumab in systemic juvenile idiopathic arthritis completed

GSK reports topline results from first of eight phase III studies of albiglutide in type 2 diabetes

Early clinical studies of CTP-499 conducted in healthy subjects

Pan-tyrosine-protein kinase inhibitor shows potential for treatment of multiple sclerosis

New VPAC2 receptor agonist demonstrates antihypertensive potential

New antiarrhythmic agent demonstrates good efficacy and safety in pilot study

Chinese researchers present new IKK-beta inhibitors

Cellzome presents novel JAK3 inhibitors

Scientists at Leo Pharma synthesize novel PDE4 inhibitors

New puerarin derivative reported by Shandong University

Cytokinetics discloses new modulators of skeletal muscle contractility

NCI commences phase I trial of AZD-7451 for gliomas

Eisai and Novartis Pharma enter agreement on COPD therapies in Japan

Alnylam Pharmaceuticals licenses InterfeRx to Sylentis

AstraZeneca receives positive CHMP opinion for vandetanib

FDA pushes back review date for Takeda's type 2 diabetes therapies

Hybrigenics initiates phase II trial of inecalcitol for psoriasis

Shionogi and Shire enter collaboration for two therapeutic agents for ADHD

Regeneron obtains FDA approval for Eylea

Starpharma reaches agreement with EMA on phase III program for VivaGel

Ajinomoto and Interprotein to collaborate on protein-protein interaction inhibitors

Mologen's phase I/II study of cell-based renal cancer therapy meets primary endpoint

FDA reaches final decision on Avastin for metastatic breast cancer

CHMP recommends extended indication for Rebif in patients with early signs of MS

GSK and Daiichi Sankyo set to launch Rotarix rotavirus vaccine in Japan